Patricia Gómez

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

José Baselga, Patricia Gómez, Richard Greil et al. · Journal of Clinical Oncology · 2013 · 351 citations · Full text

Medicine, Oncology, Pharmacology +17

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Aleix Prat, Giampaolo Bianchini, Marlène Thomas et al. · Clinical Cancer Research · 2014 · 236 citations

Medicine, Molecular Medicine, Oncology +17

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

José Baselga, J. G. M. Segalla, Henri Roché et al. · Journal of Clinical Oncology · 2012 · 163 citations · Full text

Medicine, Oncology, Pharmacology +15

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

Milvia Zambetti, Mauro Mansutti, Patricia Gómez et al. · Breast Cancer Research and Treatment · 2011 · 52 citations

Medicine, Oncology, Breast Oncology +14

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer

José Baselga, Claudio Zamagni, Patricia Gómez et al. · Clinical Breast Cancer · 2017 · 48 citations

Medicine, Oncology, Pharmacology +15